Trump’s 100% Drug Tariff: What It Means for India and the Market?

US President Donald Trump has announced a 100% import tax on branded and patented medicines from October 1, 2025. At first glance, this looks worrying, but the impact on India is not so straightforward. India exports medicines worth $8.7 billion to the US, about one-third of all pharma exports. But most of these are generic drugs (cheaper versions of medicines after patents expire). The good news is that generics are not affected by this tariff. The worry is for Indian companies that make branded or specialty medicines for global drug giants. These companies may face higher costs if their products go to the US. India’s CRDMO sector (Contract Research, Development & Manufacturing Organisations) could feel the pressure because they often work for big global pharma players. However, this move might also help India in some ways. Since the US market will look for cheaper alternatives, Indian generic drugmakers could get more business. India has big advantages – lower costs, skilled workforce, and faster delivery timelines. For the broader Indian market, the near-term effect could be mixed. Pharma stocks focused on US generics may benefit, while those linked to branded or specialty drugs might see challenges. But over time, if Indian CRDMOs invest in innovation, expand to other countries, and build stronger local supply chains, they can turn this challenge into an opportunity. In short, Trump’s tariff may cause short-term uncertainty, but it also pushes Indian pharma to innovate and expand globally, which could strengthen India’s position as the world’s pharmacy.